ID: h-a3bfd2e13a
Hypothesis
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clinical Benefits After Treatment Cessation
A specific threshold represents the point at which amyloid-driven tau pathology has been reduced below the threshold required to sustain neurodegeneration.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
🧪 Overview
A specific threshold represents the point at which amyloid-driven tau pathology has been reduced below the threshold required to sustain neurodegeneration. However, the threshold is operationally undefined—the <0.15 pg/mL value lacks prospective validation and is likely derived from cross-sectional amyloid status cutoffs, not treatment cessation studies. The proposed pragmatic trial to validate this threshold has never been conducted and carries significant ethical and investment risk.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Testosterone/ANDROGEN RECEPTOR Axis<br/>Neuronal Androgen Binding"]
B["AR Nuclear Translocation<br/>Coactivator Recruitment and Hormonal Ligand"]
C["TM4SF5 and CD82 Expression<br/>Senescent Cell Surface Marker Induction"]
D["Senolytic Target Engagement<br/>p53-Dependent Apoptosis in SASP Cells"]
E["Inflammatory Niche Remodeling<br/>SASP Factor Clearance"]
F["Neurodegenerative Niche Improvement<br/>Reduced Inflammatory Tone"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
Longitudinal p-tau217 decline correlates with slowed cognitive decline on CDR-SB
Supports
Trajectory analyses show amyloid normalization precedes p-tau217 decline in some patients
Supports
Tailoring thresholds for interpreting plasma p-tau217 levels.
Supports
CT-derived brain volumes and plasma p-Tau217 for risk stratification of amyloid positivity in early-stage Alzheimer's disease.
Contradicts
The specific threshold appears without citation and likely derives from population-level cutoffs
Contradicts
TRAILBLAZER-EXT: amyloid normalization precedes p-tau217 decline in some patients—undermines single threshold rule
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NA
No curated PDB or AlphaFold mapping for NA yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NA - Companion diagnostic target.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0125
Events (7d)
0
Price History
▲0.2%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with early Alzheimer's disease who cease anti-amyloid antibody therapy are stratified by baseline CSF p-tau217 (<0.15 pg/mL vs ≥0.15 pg/mL) and followed prospectively for 24 months post-ce | Stratified clinical progression rate difference of ≥0.5 CDR-SB points favoring the <0.15 pg/mL group at 24 months post-cessation | — no observation — | pending | 0.25 |
| IF ROC analysis is performed on CSF p-tau217 values from a treatment cessation cohort to empirically identify the optimal threshold for predicting durable clinical benefit (CDR-SB stability at 18-24 m | Empirically derived optimal threshold deviating ≥30% from 0.15 pg/mL | — no observation — | pending | 0.15 |
🔮 Falsifiable Predictions (2)
pendingconf 25%
IF patients with early Alzheimer's disease who cease anti-amyloid antibody therapy are stratified by baseline CSF p-tau217 (<0.15 pg/mL vs ≥0.15 pg/mL) and followed prospectively for 24 months post-cessation, THEN those with p-tau217 <0.15 pg/mL will demonstrate slower clinical progression (CDR-SB c
Predicted outcome: Stratified clinical progression rate difference of ≥0.5 CDR-SB points favoring the <0.15 pg/mL group at 24 months post-cessation
Falsification: No statistically significant difference (p>0.05) in CDR-SB progression between threshold-defined groups, or numerically worse outcomes in the <0.15 pg/mL group
pendingconf 15%
IF ROC analysis is performed on CSF p-tau217 values from a treatment cessation cohort to empirically identify the optimal threshold for predicting durable clinical benefit (CDR-SB stability at 18-24 months), THEN the derived threshold will differ by ≥30% from the proposed <0.15 pg/mL value (i.e., be
Predicted outcome: Empirically derived optimal threshold deviating ≥30% from 0.15 pg/mL
Falsification: The empirically derived threshold falls within ±10% of 0.15 pg/mL (i.e., 0.135-0.165 pg/mL range), indicating cross-sectional cutoffs were appropriate for cessation prediction
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.